Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Cancer Vaccines01:30

Cancer Vaccines

419
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
419
Development of Immunocompetence01:22

Development of Immunocompetence

357
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
357
Vaccinations01:51

Vaccinations

44.8K
Overview
44.8K
Conjugated Proteins02:50

Conjugated Proteins

18.4K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Cerebral Basis for Visual Discomfort and Visual Stress.

Vision (Basel, Switzerland)·2026
Same author

Paradoxical inhibition of autonomic output following cortical suppression: When inhibiting an inhibitor results in more (not less) inhibition.

Neuropsychologia·2026
Same author

Age-related changes in the attentional modulation of multisensory integration in relation to balance maintenance.

NeuroImage·2025
Same author

Improving Empiric Antibiotic Selection for Patients Hospitalized With Abdominal Infection: The INSPIRE 4 Cluster Randomized Clinical Trial.

JAMA surgery·2025
Same author

Improving Empiric Antibiotic Selection for Patients Hospitalized With Skin and Soft Tissue Infection: The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial.

JAMA internal medicine·2025
Same author

Subjective visual sensitivity in neurotypical adults: insights from a magnetic resonance spectroscopy study.

Frontiers in neuroscience·2024

Related Experiment Video

Updated: Jul 24, 2025

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
10:16

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

3.3K

Covid-19: Race For A Vaccine.

L Hayley Burgess1, Jason J Braithwaite2,3, Emily Singleton2,4

  • 1HCA Healthcare, Clinical Operations Group, Nashville, TN.

HCA Healthcare Journal of Medicine
|July 10, 2023
PubMed
Summary

The COVID-19 pandemic urgently requires a vaccine. Operation Warp Speed expedited development, yielding highly effective vaccines from Moderna and Pfizer, but public confidence remains a challenge.

Keywords:
COVID-19COVID-19 vaccinesSARS-CoV-2coronavirus infectionepidemicimmunizationmessenger RNApandemicpatient safetyvaccinesviral vaccines/adverse effects

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
00:10

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K
Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

4.6K

Related Experiment Videos

Last Updated: Jul 24, 2025

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
10:16

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

Published on: August 17, 2022

3.3K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
00:10

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.6K
Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

4.6K

Area of Science:

  • Vaccinology
  • Epidemiology
  • Public Health

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, has resulted in millions of cases and deaths globally.
  • Traditional vaccine development timelines are lengthy (10+ years) with low market entry probability.
  • No effective coronavirus vaccine was commercially available prior to these efforts.

Purpose of the Study:

  • To accelerate the development and delivery of safe and effective COVID-19 vaccines.
  • To address the urgent need for a vaccine to mitigate the global impact of the pandemic.
  • To evaluate the efficacy and safety of leading vaccine candidates.

Main Methods:

  • Operation Warp Speed coordinated government support, parallel clinical trials, and early manufacturing de-risking.
  • Real-time safety and efficacy data evaluation by the U.S. Food & Drug Administration (FDA).
  • Monitoring of vaccine efficacy rates for leading candidates.

Main Results:

  • Two frontrunner vaccine candidates demonstrated high efficacy: Moderna at 94.1% and Pfizer at 95.0%.
  • Development timelines were significantly compressed compared to historical averages.
  • Despite high efficacy, national surveys indicate low public confidence (<50% willingness to vaccinate).

Conclusions:

  • Accelerated vaccine development for COVID-19 has been successful in producing highly effective candidates.
  • Achieving herd immunity requires high vaccine efficacy (70-80%) and vaccination rates (70-80%).
  • Significant public education and promotion efforts are necessary to build vaccine confidence and achieve population protection.